Abacavir
- Atc Codes:J05AF06
- CAS Codes:188062-50-2#168146-84-7#136470-78-5
- PHARMGKB ID:188062-50-2#168146-84-7#136470-78-5
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Ziagen; Belgium: Ziagen; Bulgaria: Ziagen; Cyprus: Ziagen; Czech Republic: Ziagen; Denmark: Ziagen; Estonia: Ziagen; Finland: Ziagen; France: Ziagen; Germany: Ziagen; Greece: Ziagen; Hungary: Ziagen; Ireland: Ziagen; Italy: Ziagen; Latvia: Ziagen; Lithuania: Ziagen; Luxembourg: Ziagen; Malta: Ziagen; Netherlands: Ziagen; Poland: Ziagen; Portugal: Ziagen; Romania: Ziagen; Slovakia: Ziagen; Slovenia: Ziagen; Spain: Ziagen; Sweden: Ziagen; UK: Ziagen.
North America
Canada: Ziagen; USA: Ziagen.
Latin America
Argentina: Abacavir, Filabac, Finecil, Panka, Plusabcir, Zepril, Ziagenavir; Brazil: Ziagenavir; Mexico: Ziagenavir.
Asia
Japan: Ziagen.
Drug combinations
Abacavir and Lamivudine
Abacavir, Lamivudine, and Zidovudine
Chemistry
Abacavir Sulfate: (C~14~H~18~N~6~O)~2~ H~2~SO~4~. Mw: 670.74. (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol sulfate (2:1). CAS-188062-50-2 (1997).
Abacavir Succinate: C~14~H~18~N~6~O C~4~H~6~O~4~. Mw: 404.42. 2-Cyclopentene-1-methanol, 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-, (1S-cis)-, butanedioate (1:1). CAS-168146-84-7; CAS-136470-78-5 (abacavir)(1996).
Pharmacologic Category
Anti-Infective Agents; Antiretrovirals; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. (ATC-Code: J05AF06).
Mechanism of action
Abacavir is phosphorylated to carbovir triphosphate, which interferes with HIV viral RNA-dependent DNA polymerase, inhibiting viral replication.
Therapeutic use
Treatment of HIV infections in combination with other antiretroviral agents.
Pregnancy and lactiation implications
Risk of lactic acidosis and liver damage in pregnant women. Contraindicated during lactation.
Unlabeled use
Contraindications
Hypersensitivity to abacavir (or carbovir) or any component of the formulation. Hepatic impairment.
Warnings and precautions
Hypersensitivity reactions have occurred (increased risk in patients with HLA-B*5701 allele). Lactic acidosis and severe hepatomegaly with steatosis have been reported (caution in risk factors for liver disease). Caution in hepatic dysfunction (contraindicated in moderate-to-severe dysfunction) or in risk factors for coronary heart disease. Immune reconstitution syndrome may develop. May cause redistribution of fat. Should always be used as part of a multidrug regimen.